Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Advertising & Marketing

Sales

Legal & Regulatory

Acquisition & Integration

Goodwill impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Teladoc

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002, by George Byron Brooks and Gary Wald and is headquartered in Purchase, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teladoc reports solid Q4 growth, eyes revenue optimization strategies

Teladoc's Q4 performance showed revenue growth and margin focus, with BetterHelp contributing significantly to profitability.
The company's strategic focus on virtual care expansion and revenue optimization positions Teladoc for continued success in the healthcare market.
While facing internal restructuring challenges, Teladoc's emphasis on growth drivers and operational efficiency presents opportunities for future growth and market leadership.

Teladoc Health excels in Q1, eyes growth and efficiency

Teladoc Health's Q1 performance was strong, with revenue exceeding expectations.
The company is focused on efficiency, innovation, and driving value in virtual care.
BetterHelp segment showed growth and stability, with improving margins expected.
Opportunities exist to capitalize on ad pricing stability and consumer behavior trends.

Teladoc surpasses revenue expectations, focuses on innovation and growth

Teladoc's Q2 performance exceeded expectations, with strong revenue growth and improved margins in both segments. The company's strategic focus on whole-person care, weight management, and AI enhancements positions it well for future growth. Challenges include managing drug costs and private company valuations, while opportunities lie in virtual care demand and strategic M&A.
Teladoc's financial strength, commitment to innovation, and focus on efficiency improvements are key strengths driving its performance. The company's ability to navigate challenges and capitalize on opportunities in the evolving healthcare landscape underscores its resilience and growth potential.

Teladoc Health surpasses Q3 expectations, eyes margin expansion in '24

Teladoc Health's Q3 performance exceeded expectations, driven by revenue growth and margin improvements.
The company is focused on enhancing cost efficiencies, profitability, and driving margin expansion.
Stable pricing environment and strong client demand present opportunities for future growth.
Operational review and strategic initiatives position Teladoc for continued success in the healthcare sector.

Teladoc reports robust 2023 earnings, eyes growth amid marketing challenges

Teladoc delivered strong financial performance in 2023 with notable growth in adjusted EBITDA and revenue. The company faces challenges in BetterHelp marketing yields and delayed consumer engagement efforts.
However, Teladoc's strategic strengths lie in its long-term outlook for revenue growth, margin expansion, and cost-saving initiatives. Opportunities exist in optimizing sales force structure and capital deployment for future growth.
Overall, Teladoc's focus on profitability, growth optimization, and strategic capital allocation positions it well for sustained success in the telehealth industry.

Teladoc Health reports solid Q1 performance amidst revenue challenges

Teladoc Health's Q1 2024 performance showcased revenue growth in Integrated Care but challenges in BetterHelp segment revenue and margin management.
The company's financial strength, product portfolio, and cost initiatives position it well for growth opportunities and strategic market positioning.
Addressing challenges in ad spend management and focusing on international market efficiency are key to unlocking growth potential and improving financial performance.
Overall, Teladoc's performance, strengths, challenges, and opportunities reflect a dynamic landscape with strategic focus on sustainable growth and operational efficiency.

Teladoc Health reports Q2 revenue dip, EBITDA growth; addresses challenges

Teladoc Health's Q2 2024 performance showed mixed results with revenue decline but EBITDA growth. The company is leveraging strengths in patient safety and technology while addressing challenges in customer acquisition costs. Opportunities lie in operational efficiency, insurance coverage access, and international expansion.

Teladoc Health reports Q3 revenue decline but strategic growth

Teladoc Health's Q3 2024 performance reflects mixed results with revenue decline but strategic growth in the Integrated Care segment.
The company's focus on customer-centric strategies, technology, and clinical excellence positions it well for future success and market leadership.
Challenges in revenue decline and expense management require Teladoc Health to balance short-term financial performance with long-term growth objectives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002, by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in Purchase, NY.

NEW YORK , Aug. 1, 2022 /PRNewswire/ -- Attention Teladoc Health, Inc. ("Teladoc") (NYSE: TDOC) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between October 28, 2021 and April 27, 2022. If you suffered a loss on your investment in Teladoc, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Teladoc Investors of a Lead Plaintiff Deadline of August 5, 2022

New York, New York--(Newsfile Corp. - July 31, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Teladoc Health, Inc. (NYSE: TDOC) between October 28, 2021 and April 27, 2022, both dates inclusive (the "Class Period"), of the important August 5, 2022 lead plaintiff deadline.

TDOC FRIDAY DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Teladoc Health, Inc. Investors With Losses Over $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action - TDOC

Amazon

1Life Healthcare

Between subpar earnings and Amazon's potential purchase of One Medical, Teladoc investors have their hands full of late.

Here's What Amazon's Potential Acquisition of One Medical Means for Teladoc Health Investors

Could Teladoc Stock Help You Become a Millionaire?

PURCHASE, NY, July 30, 2022 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, is providing free, 24/7 general medical telehealth visits to residents, first responders and others in Kentucky directly impacted by the severe storms and devastating flooding that have affected the state. Individuals from eastern Kentucky who are hardest hit and are now being displaced can seek treatment from a licensed health care professional for any non-emergency illness by calling Teladoc directly at 855-225-5032.

Teladoc Health Is Providing Free Virtual Health Care Services to Those Impacted by Kentucky Flooding

Teladoc has disappointed investors more than once this year.

20 Words That Could Completely Change Your Opinion of Teladoc

NEW ORLEANS , July 29, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 5, 2022 to file lead plaintiff applications in a securities class action lawsuit against Teladoc Health, Inc. (NYSE: TDOC), if they purchased the Company's securities between October 28, 2021 and April 27, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.

TELADOC HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teladoc Health, Inc. - TDOC

Investors weren't happy at all with the company's latest set of quarterly results.

Why Teladoc Health Was a Sickly Stock This Week

NEW YORK--(BUSINESS WIRE)---- $TDOC #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Teladoc Health, Inc. (“Teladoc” or the “Company”) (NASDAQ: TDOC) securities from October 28, 2021 through April 27, 2022, both dates inclusive (the “Class Period”). Investors have until August 5, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Teladoc provi

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Teladoc Health, Inc. (TDOC) Investors and Encourages Investors to Contact the Firm Before August 5, 2022

Roku

ARK Innovation ETF

Despite Ark Invest's continuation of poor performance this year, investors have poured nearly $2 billion into the speculative tech ETF.

Ark Invest's flagship fund falters amid broader tech rally after earnings implosion from top holdings Roku and Teladoc

Coinbase

Block

Tesla

Source: rhendrikdwenz via Shutterstock [Editor's note: “5 Reasons ‘Cathie Wood Stocks' Could Double Over the Next 12 Months ” was previously published in January 2022 . It has since been updated to include the most relevant information available.

5 Reasons ‘Cathie Wood Stocks' Could Double Over the Next 12 Months

Is Teladoc a Bad-News Buy?

The virtual care leader likely overpaid when it acquired Livongo.

Why Teladoc Stock Plunged Today

Teladoc (TDOC) stock is falling alongside the release of its Q2 earnings report

Teladoc (TDOC) Stock Plummets on Q2 Loss, Weak Guidance

Although this quarter was better than the last one, we're not out of the woods yet.

Why Teladoc Stock Crashed After Earnings

There was some good news in the midst of Teladoc's disappointing Q2 results.

Teladoc Stock: 3 Bright Spots Investors Are Ignoring

The remote healthcare provider posts a wider-than-expected quarterly loss after recording a $3 billion impairment charge.

Teladoc Stock Sinks on Wider Loss and Weak Guidance

CEDARHURST, N.Y. , July 27, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Teladoc Health, Inc. (NYSE: TDOC), if they purchased the Company's securities between October 28, 2021 and April 27, 2022, inclusive (the "Class Period").

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Teladoc Health, Inc. - TDOC

Teladoc Health, Inc. (NYSE:TDOC ) Q2 2022 Earnings Conference Call July 27, 2022 4:30 PM ET Company Participants Patrick Feeley - Vice President & Investor Relations Jason Gorevic - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Lisa Gill - JPMorgan Sandy Draper - Guggenheim Securities Richard Close - Canaccord Genuity Stephanie Davis - SVB Leerink Sean Dodge - RBC Charles Rhyee - Cowen Daniel Grosslight - Citi George Hill - Deutsche Bank Jessica Tassan - Piper Sandler A.J. Rice - Credit Suisse Stan Berenshteyn - Wells Fargo David Larsen - BTIG Operator Hello, and welcome to today's Teladoc Health Q2 Earnings Call.

Teladoc Health, Inc. (TDOC) CEO Jason Gorevic on Q2 2022 Results - Earnings Call Transcript

Teladoc Health Inc (NYSE: TDOC) shares are down 25% in extended trading after the telemedicine company reported wider-than-expected loss for its fiscal second quarter and lowered its full-year guidance. Key takeaways from Teladoc Q2 earnings report Lost $3.1 billion versus the year-ago figure of $133.8 million Per-share loss of $19.

Teladoc shares down 25% in extended trading: how come?

New York, New York--(Newsfile Corp. - July 27, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Teladoc Health, Inc. (NYSE: TDOC) between October 28, 2021 and April 27, 2022, both dates inclusive (the "Class Period"), of the important August 5, 2022 lead plaintiff deadline.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Teladoc Health, Inc. Investors With Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action - TDOC

Shares of Teladoc Inc. plunged more than 11% in after-hours trading Thursday after the telehealth company took another multibillion-dollar impairment charge, helping to bring its total losses for the first six months of the year up to nearly $10 billion.

Teladoc loses $3 billion in three months, stock plummets

PURCHASE, NY, July 27, 2022 (GLOBE NEWSWIRE) --  Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the second quarter ended June 30, 2022.

Teladoc Health Reports Second-Quarter 2022 Results

Fate Therapeutics

MercadoLibre

Intellia Therapeutics

Zoom Video

Cathie Wood stocks trading at a discount is our topic for today. The prominent fund manager and her team focus on disruptive innovation, considered by many to be a new paradigm in investing.

7 Cathie Wood Stocks Trading at a Discount Right Now

New York, New York--(Newsfile Corp. - July 25, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Teladoc Health, Inc. (NYSE: TDOC) between October 28, 2021 and April 27, 2022, both dates inclusive (the "Class Period"), of the important August 5, 2022 lead plaintiff deadline.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Teladoc Health, Inc. Investors to Secure Counsel Before Important August 5 Deadline in Securities Class Action - TDOC

News for Teladoc Stock (TDOC)